Stifel raised the firm’s price target on Relay Therapeutics to $30 from $25 and keeps a Buy rating on the shares. The firm is increasing its peak sales estimates for RLY-2608 due to the HR+ breast cancer model and the firm’s recent deep dove covering the treatment landscape, the analyst tells investors. Further, Stifel is optimistic on the upcoming Phase 1 update for RLY-2608/fulvestrant.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RLAY:
- Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
- Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential
- Relay Therapeutics to sell 2.5M shares at $12.00 in private placement
- Relay Therapeutics Announces $30 Million Private Placement Financing
